Carl Zeiss Vision announced today a partnership with the American Cancer Society to increase awareness of the importance of full UV protection for both eyes and skin. The partnership will help raise funds for the ACS mission to fight cancer from every angle.
San Diego, USA | 20 March 2019 | ZEISS Vision Care
“ZEISS is proud to partner with the American Cancer Society in an effort to help consumers protect their eyes and eyelids from UV rays,” said Andrew Hyncik, vice president of marketing for ZEISS Vision Care. “Today, an estimated 80 percent of all clear eyeglass materials do not fully block all UV up to the internationally recognized standard of 400nm.”
In April 2018, the eyeglass lens manufacturer launched ZEISS UVProtect Technology across its ZEISS portfolio of clear eyeglass lenses. The new technology offers full 400nm of protection, a significant step up from the current industry standard of 380nm with the 20nm difference actually accounting for 40 percent of total UV radiation. The partnership will raise awareness about the importance of UV protection and support the mission of the American Cancer Society.
ZEISS Vision is working with eye care professional partners as part of its ZEISS UVProtect Technology campaign to make full UV protection up to 400nm top of mind for both consumers and eye care providers.
“With eyeglass technology now offering the same amount of UV protection commonly found in premium sunglasses, ZEISS is on a mission to ensure patients with prescription eyeglasses fully protect their eyes and eyelids from UV rays, all day, every day,” said Hyncik.
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling more than 5.8 billion euros in its four segments Industrial Quality & Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology (status: 30 September 2018).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future far beyond the optics and optoelectronics industries. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership.
With around 30,000 employees, ZEISS is represented in nearly 50 countries, with approximately 60 of its own sales and service companies and 30 manufacturing and development centers around the globe. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.
For more information, please visit www.zeiss.com
ZEISS Vision Care
ZEISS Vision Care is one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments. The area is part of the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand.